| Literature DB >> 26092709 |
Shiva Sharma1, Mitchel Barry2, David J Gallagher1, Malcolm Kell1, Virgilio Sacchini3.
Abstract
Triple negative breast cancers (TNBCs) represent a distinct subgroup of breast cancers with an immunohistochemical phenotype that is negative for oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). The aim of this article is to provide a broad overview of recent developments in the diagnosis and management of TNBC for surgical oncologists. This overview discusses the subtypes of TNBC and the relationship between this type of breast cancer and the BRCA1 gene. In addition, the article explores recent advances in the treatment of TNBC from a surgical, radiation, and medical oncology point of view. Lastly, evolving therapeutic strategies that have potential to enhance outcomes for patients with TNBC are also discussed.Entities:
Keywords: Breast surgery oncology; Review; Triple negative breast cancer
Mesh：
Substances：
Year: 2015 PMID： 26092709 DOI： 10.1016/j.suronc.2015.06.007
Source DB: PubMed Journal: Surg Oncol ISSN： 0960-7404 Impact factor: 3.279